Open-label, exploratory, pharmacodynamic (PD) dose-finding study of intravenous RO5323441 in patients with metastatic treatment-refractory colorectal and ovarian cancer
Phase of Trial: Phase I
Latest Information Update: 01 Apr 2017
At a glance
- Drugs THR 317 (Primary)
- Indications Colorectal cancer; Ovarian cancer
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Roche
- 15 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Jan 2011 Planned End Date changed from 1 Nov 2010 to 1 Dec 2010 as reported by ClinicalTrials.gov.
- 15 Jul 2010 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health)(NCT01148758).